# Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Study · id `cardio:ct-nct02749890` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02749890](<https://clinicaltrials.gov/study/NCT02749890>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02749890

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.

## Technical summary

Registry record NCT02749890. Randomized; no masking; primary purpose treatment. Start 2016-05-09 (actual); primary completion 2018-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 321 participants (enrolled count; ClinicalTrials.gov record NCT02749890, source copy `cardio:ctgov-nct02749890-2020-06-16`, retrieved 2026-10-26)
- Started: 2016-05-09 (actual) (ClinicalTrials.gov record NCT02749890, source copy `cardio:ctgov-nct02749890-2020-06-16`, retrieved 2026-10-26)
- Primary completion: 2018-05 (actual) (ClinicalTrials.gov record NCT02749890, source copy `cardio:ctgov-nct02749890-2020-06-16`, retrieved 2026-10-26)
- Completion: 2018-05 (actual) (ClinicalTrials.gov record NCT02749890, source copy `cardio:ctgov-nct02749890-2020-06-16`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02749890, source copy `cardio:ctgov-nct02749890-2020-06-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02749890-2020-06-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
- Acronym: LIXILAN JP-O1
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin glargine/Lixisenatide (HOE901/AVE0010)
- Intervention (Drug): Lixisenatide (AVE0010)
- Intervention (Drug): Oral anti-diabetic drugs
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial (`cardio:pubmed-32295808`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fb9ecb18f268a32d1bfddeaf102174de224db915335cfb9b300309f1293dff5b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
